Manqing Cao

793 total citations
17 papers, 601 citations indexed

About

Manqing Cao is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Manqing Cao has authored 17 papers receiving a total of 601 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 8 papers in Oncology and 8 papers in Cancer Research. Recurrent topics in Manqing Cao's work include Cancer, Hypoxia, and Metabolism (5 papers), Hepatocellular Carcinoma Treatment and Prognosis (4 papers) and Cancer Mechanisms and Therapy (3 papers). Manqing Cao is often cited by papers focused on Cancer, Hypoxia, and Metabolism (5 papers), Hepatocellular Carcinoma Treatment and Prognosis (4 papers) and Cancer Mechanisms and Therapy (3 papers). Manqing Cao collaborates with scholars based in China, Ethiopia and South Africa. Manqing Cao's co-authors include Ti Zhang, Hui‐Chuan Sun, Xiao‐Dong Zhu, Chengdong Qin, Dongmei Gao, De-Ning Ma, Chenghao Wang, Zhao–You Tang, A‐Bin You and Kangshuai Li and has published in prestigious journals such as The FASEB Journal, Cell Death and Disease and Journal of Hematology & Oncology.

In The Last Decade

Manqing Cao

17 papers receiving 598 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Manqing Cao China 11 421 309 125 57 50 17 601
Yanqing Wu China 10 428 1.0× 318 1.0× 111 0.9× 57 1.0× 46 0.9× 16 572
Chengdong Qin China 10 358 0.9× 303 1.0× 105 0.8× 45 0.8× 35 0.7× 19 545
Guang Tan China 12 333 0.8× 300 1.0× 111 0.9× 53 0.9× 28 0.6× 22 505
I‐Hsiao Chung Taiwan 16 446 1.1× 373 1.2× 75 0.6× 60 1.1× 24 0.5× 18 644
Ketuan Huang China 14 317 0.8× 270 0.9× 134 1.1× 136 2.4× 29 0.6× 32 517
Yaliang Lan China 9 360 0.9× 296 1.0× 77 0.6× 55 1.0× 19 0.4× 12 526
Chuanyong Zhang China 13 382 0.9× 231 0.7× 156 1.2× 49 0.9× 51 1.0× 25 630
Mitsuhiro Hishida Japan 12 309 0.7× 152 0.5× 91 0.7× 82 1.4× 65 1.3× 23 484
Noélia Che China 7 282 0.7× 167 0.5× 103 0.8× 44 0.8× 82 1.6× 10 424
Longrong Wang China 14 327 0.8× 248 0.8× 114 0.9× 112 2.0× 53 1.1× 26 560

Countries citing papers authored by Manqing Cao

Since Specialization
Citations

This map shows the geographic impact of Manqing Cao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Manqing Cao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Manqing Cao more than expected).

Fields of papers citing papers by Manqing Cao

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Manqing Cao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Manqing Cao. The network helps show where Manqing Cao may publish in the future.

Co-authorship network of co-authors of Manqing Cao

This figure shows the co-authorship network connecting the top 25 collaborators of Manqing Cao. A scholar is included among the top collaborators of Manqing Cao based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Manqing Cao. Manqing Cao is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Liu, Shaoqing, Jialei Weng, Manqing Cao, et al.. (2024). FGFR2 fusion/rearrangement is associated with favorable prognosis and immunoactivation in patients with intrahepatic cholangiocarcinoma. The Oncologist. 29(12). e1734–e1747. 1 indexed citations
2.
Zhang, Lu, Manqing Cao, Huaqi Wang, et al.. (2023). Thioredoxin facilitates hepatocellular carcinoma stemness and metastasis by increasing BACH1 stability to activate the AKT / mTOR pathway. The FASEB Journal. 37(6). e22943–e22943. 8 indexed citations
3.
Zhang, Chao, Lisha Qi, Jun Cai, et al.. (2023). Clinicomics-guided distant metastasis prediction in breast cancer via artificial intelligence. BMC Cancer. 23(1). 239–239. 10 indexed citations
4.
Zhang, Su, Xuejiao Yang, Zhenyu Hou, et al.. (2022). Drug-related adverse events potentially predict the efficacy of apatinib on advanced hepatocellular carcinoma. BMC Gastroenterology. 22(1). 441–441. 2 indexed citations
5.
Wang, Huaqi, Zhenyu Hou, Xuejiao Yang, et al.. (2021). The Neutrophil-to-Lymphocyte Ratio (NLR) Predicts the Prognosis of Unresectable Intermediate and Advanced Hepatocellular Carcinoma Treated with Apatinib. Cancer Management and Research. Volume 13. 6989–6998. 6 indexed citations
6.
Zhang, Kewei, Dong Wang, Hao Cai, et al.. (2021). IL‑6 plays a crucial role in epithelial‑mesenchymal transition and pro‑metastasis induced by sorafenib in liver cancer. Oncology Reports. 45(3). 1105–1117. 15 indexed citations
7.
Li, Kangshuai, Xiao‐Dong Zhu, Hongda Liu, et al.. (2020). NT5DC2 promotes tumor cell proliferation by stabilizing EGFR in hepatocellular carcinoma. Cell Death and Disease. 11(5). 335–335. 45 indexed citations
8.
Cao, Manqing, et al.. (2020). Apatinib as an alternative therapy for advanced hepatocellular carcinoma. World Journal of Hepatology. 12(10). 766–774. 15 indexed citations
9.
Cao, Manqing, A‐Bin You, Su Zhang, et al.. (2020). Cross talk between oxidative stress and hypoxia via thioredoxin and HIF‐2α drives metastasis of hepatocellular carcinoma. The FASEB Journal. 34(4). 5892–5905. 22 indexed citations
10.
Cao, Manqing, A‐Bin You, Xiao‐Dong Zhu, et al.. (2018). miR-182-5p promotes hepatocellular carcinoma progression by repressing FOXO3a. Journal of Hematology & Oncology. 11(1). 12–12. 177 indexed citations
11.
Sun, Lin, Manqing Cao, Hongyuan Zhou, et al.. (2017). Decreased expression of acetyl‐CoA synthase 2 promotes metastasis and predicts poor prognosis in hepatocellular carcinoma. Cancer Science. 108(7). 1338–1346. 41 indexed citations
12.
Cao, Manqing, A‐Bin You, Hongyuan Zhou, et al.. (2017). [Effect of HIF-2α on regulating CDCP1 to promote hepatocellular carcinoma metastasis].. PubMed. 39(1). 18–23. 1 indexed citations
13.
Qin, Chengdong, De-Ning Ma, Zhenggang Ren, et al.. (2017). Astragaloside IV inhibits metastasis in hepatoma cells through the suppression of epithelial-mesenchymal transition via the Akt/GSK-3β/β-catenin pathway. Oncology Reports. 37(3). 1725–1735. 43 indexed citations
14.
You, A‐Bin, Manqing Cao, Bingfeng Zuo, et al.. (2016). Metformin sensitizes sorafenib to inhibit postoperative recurrence and metastasis of hepatocellular carcinoma in orthotopic mouse models. Journal of Hematology & Oncology. 9(1). 20–20. 57 indexed citations
15.
Ma, De-Ning, Zong‐Tao Chai, Xiao‐Dong Zhu, et al.. (2016). MicroRNA-26a suppresses epithelial-mesenchymal transition in human hepatocellular carcinoma by repressing enhancer of zeste homolog 2. Journal of Hematology & Oncology. 9(1). 1–1. 102 indexed citations
16.
Cao, Manqing, A‐Bin You, Hongyuan Zhou, et al.. (2016). Metformin inhibits the prometastatic effect of sorafenib in hepatocellular carcinoma by upregulating the expression of TIP30. Cancer Science. 107(4). 507–513. 31 indexed citations
17.
Cao, Manqing, Hongyuan Zhou, A‐Bin You, et al.. (2015). HIF-2α regulates CDCP1 to promote PKCδ-mediated migration in hepatocellular carcinoma. Tumor Biology. 37(2). 1651–1662. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yanqing Wu Breakdown of academic impact, for papers by Chengdong Qin Breakdown of academic impact, for papers by Guang Tan Breakdown of academic impact, for papers by I‐Hsiao Chung Breakdown of academic impact, for papers by Ketuan Huang Breakdown of academic impact, for papers by Yaliang Lan Breakdown of academic impact, for papers by Chuanyong Zhang Breakdown of academic impact, for papers by Mitsuhiro Hishida Breakdown of academic impact, for papers by Noélia Che Breakdown of academic impact, for papers by Longrong Wang
Rankless by CCL
2026